| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/1078-0432.CCR-08-2785 |
| P8608 | Fatcat ID | release_o6s7otlndzbutbyg6jnya3nopy |
| P698 | PubMed publication ID | 19509172 |
| P50 | author | Simon Harrison | Q47348076 |
| Mark Bishton | Q56670342 | ||
| P2093 | author name string | H Miles Prince | |
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 3958-3969 | |
| P577 | publication date | 2009-06-09 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Clinical studies of histone deacetylase inhibitors | |
| P478 | volume | 15 |
| Q35799771 | A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIM-dependent apoptosis in head and neck cancer. |
| Q39248784 | A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax(®)). |
| Q26852571 | A perspective on dietary phytochemicals and cancer chemoprevention: oxidative stress, nrf2, and epigenomics |
| Q33410997 | A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma |
| Q33394863 | A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors |
| Q33402619 | A phase I trial of oral administration of panobinostat in combination with paclitaxel and carboplatin in patients with solid tumors |
| Q43225251 | A structure-activity relationship study on multi-heterocyclic molecules: two linked thiazoles are required for cytotoxic activity |
| Q36342282 | A systems biology approach to identify molecular pathways altered by HDAC inhibition in osteosarcoma |
| Q47836540 | AN-7, a butyric acid prodrug, sensitizes cutaneous T-cell lymphoma cell lines to doxorubicin via inhibition of DNA double strand breaks repair |
| Q48764064 | ATF3 Repression of BCL-XL Determines Apoptotic Sensitivity to HDAC Inhibitors across Tumor Types. |
| Q28544949 | Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy |
| Q36187278 | Amino acid starvation induces reactivation of silenced transgenes and latent HIV-1 provirus via down-regulation of histone deacetylase 4 (HDAC4) |
| Q33731197 | Amphiregulin promotes resistance to gefitinib in nonsmall cell lung cancer cells by regulating Ku70 acetylation |
| Q37445211 | Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors. |
| Q28482468 | Anticancer activity of MPT0E028, a novel potent histone deacetylase inhibitor, in human colorectal cancer HCT116 cells in vitro and in vivo |
| Q33408198 | Application of hematological toxicity modeling in clinical development of abexinostat (S-78454, PCI-24781), a new histone deacetylase inhibitor. |
| Q38067646 | Attacking the HIV reservoir from the immune and viral perspective |
| Q28577251 | Auto-acetylation stabilizes p300 in cardiac myocytes during acute oxidative stress, promoting STAT3 accumulation and cell survival |
| Q34660049 | Autotaxin is induced by TSA through HDAC3 and HDAC7 inhibition and antagonizes the TSA-induced cell apoptosis |
| Q47820744 | BEBT-908: A novel potent PI3K/HDAC inhibitor against diffuse large B-cell lymphoma |
| Q38735639 | Belinostat and vincristine demonstrate mutually synergistic cytotoxicity associated with mitotic arrest and inhibition of polyploidy in a preclinical model of aggressive diffuse large B cell lymphoma. |
| Q37787304 | Benefits of histone deacetylase inhibitors for acute brain injury: a systematic review of animal studies. |
| Q34559028 | Blocking the class I histone deacetylase ameliorates renal fibrosis and inhibits renal fibroblast activation via modulating TGF-beta and EGFR signaling |
| Q42573635 | Cancer DNA methylation: molecular mechanisms and clinical implications |
| Q43226742 | Cancer epigenetics: new therapies and new challenges. |
| Q35040811 | Cardiac HDAC6 catalytic activity is induced in response to chronic hypertension |
| Q30485542 | ChromoHub: a data hub for navigators of chromatin-mediated signalling |
| Q34318452 | Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer |
| Q38443887 | Combination of the histone deacetylase inhibitor depsipeptide and 5-fluorouracil upregulates major histocompatibility complex class II and p21 genes and activates caspase-3/7 in human colon cancer HCT-116 cells. |
| Q35968727 | Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib |
| Q36537920 | Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer |
| Q35106637 | Combining the ABL1 kinase inhibitor ponatinib and the histone deacetylase inhibitor vorinostat: a potential treatment for BCR-ABL-positive leukemia |
| Q41885967 | Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation |
| Q48308220 | Comparison of the anticancer properties of a novel valproic acid prodrug to leading histone deacetylase inhibitors. |
| Q34968517 | Cross talk between histone deacetylase 4 and STAT6 in the transcriptional regulation of arginase 1 during mouse dendritic cell differentiation |
| Q60920155 | Crosstalk between Epigenetic Modulations in Valproic Acid Deactivated Hepatic Stellate Cells: An Integrated Protein and miRNA Profiling Study |
| Q37847179 | Current status of agents active against the T315I chronic myeloid leukemia phenotype |
| Q38655572 | Cutaneous T cell Lymphoma: an Update on Pathogenesis and Systemic Therapy |
| Q37944565 | Cutaneous T-cell lymphoma: 2011 update on diagnosis, risk-stratification, and management |
| Q27024076 | Cutaneous T-cell lymphoma: 2014 update on diagnosis, risk-stratification, and management |
| Q36470196 | Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management |
| Q48034709 | Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management. |
| Q37967108 | Cutaneous lymphomas: molecular pathways leading to new drugs |
| Q37883042 | Cytosine methyltransferases as tumor markers |
| Q41808915 | Deacetylase inhibitors - focus on non-histone targets and effects |
| Q47913286 | Design, Synthesis, and Biological Evaluation of the First c-Met/HDAC Inhibitors Based on Pyridazinone Derivatives |
| Q39430288 | Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide |
| Q33622342 | Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer? |
| Q33649465 | Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity |
| Q42757408 | Distinct and redundant functions of histone deacetylases HDAC1 and HDAC2 in proliferation and tumorigenesis. |
| Q34093054 | Druggability of methyl-lysine binding sites |
| Q39402126 | Early prediction of response to Vorinostat in an orthotopic rat glioma model |
| Q52781314 | Effects of histone deacetylase inhibitory prodrugs on epigenetic changes and DNA damage response in tumor and heart of glioblastoma xenograft. |
| Q38924713 | Effects of suberoylanilide hydroxamic acid (SAHA) combined with paclitaxel (PTX) on paclitaxel-resistant ovarian cancer cells and insights into the underlying mechanisms |
| Q37809875 | Emerging role of the histone deacetylase inhibitor romidepsin in hematologic malignancies |
| Q38155507 | Emerging signaling pathways in hepatocellular carcinoma. |
| Q37925846 | Entinostat for treatment of solid tumors and hematologic malignancies |
| Q38741783 | Entinostat: a promising treatment option for patients with advanced breast cancer |
| Q37116613 | Epigenetic changes: a common theme in acute myelogenous leukemogenesis |
| Q38107626 | Epigenetic control of cytokine gene expression: regulation of the TNF/LT locus and T helper cell differentiation |
| Q53098086 | Epigenetic drug combination induces genome-wide demethylation and altered gene expression in neuro-ectodermal tumor-derived cell lines. |
| Q35753421 | Epigenetic enhancement of BDNF signaling rescues synaptic plasticity in aging |
| Q29616621 | Epigenetic protein families: a new frontier for drug discovery |
| Q51733858 | Epigenetic therapies - a new direction in clinical medicine. |
| Q36222932 | Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeuti |
| Q36409626 | Epigenetics and the transition from acute to chronic pain |
| Q36449057 | Epigenetics as a therapeutic target in breast cancer |
| Q35726371 | Epigenetics in diagnosis, prognostic assessment and treatment of cancer: an update |
| Q37768267 | Epigenetics in pain and analgesia: an imminent research field |
| Q26823403 | Epigenomics of leukemia: from mechanisms to therapeutic applications |
| Q89987510 | Expression of Stromal Progesterone Receptor and Differential Methylation Patterns in the Endometrium May Correlate with Response to Progesterone Therapy in Endometrial Complex Atypical Hyperplasia |
| Q31117873 | Finding Inspiration in the Protein Data Bank to Chemically Antagonize Readers of the Histone Code |
| Q34567084 | Finding a cure for HIV: will it ever be achievable? |
| Q33410544 | First-in-human, pharmacokinetic and pharmacodynamic phase I study of Resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumors |
| Q28477038 | Gene expression signature analysis identifies vorinostat as a candidate therapy for gastric cancer |
| Q41128716 | Green tea polyphenols causes cell cycle arrest and apoptosis in prostate cancer cells by suppressing class I histone deacetylases |
| Q33927370 | Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo |
| Q28486529 | HDAC inhibition induces increased choline uptake and elevated phosphocholine levels in MCF7 breast cancer cells |
| Q37956178 | HDAC inhibitors in HIV. |
| Q57478514 | HDAC6 inhibition protects cardiomyocytes against doxorubicin-induced acute damage by improving α-tubulin acetylation |
| Q34106191 | HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat |
| Q41923633 | Histone Deacetylase Inhibitors: Synthesis of Cyclic Tetrapeptides and their Triazole Analogues |
| Q64274976 | Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas |
| Q35744910 | Histone Deacetylases Inhibitors in the Treatment of Retinal Degenerative Diseases: Overview and Perspectives |
| Q28487649 | Histone acetylation-mediated regulation of the Hippo pathway |
| Q36645808 | Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents |
| Q35733719 | Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents |
| Q38740003 | Histone deacetylase inhibitors enhance CD1d-dependent NKT cell responses to lymphoma |
| Q34326588 | Histone deacetylase inhibitors facilitate dihydroartemisinin-induced apoptosis in liver cancer in vitro and in vivo |
| Q35667942 | Histone deacetylase inhibitors globally enhance h3/h4 tail acetylation without affecting h3 lysine 56 acetylation |
| Q34414440 | Histone deacetylase inhibitors in Hodgkin lymphoma |
| Q37777594 | Histone deacetylase inhibitors in lymphoma |
| Q34416994 | Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors |
| Q43061101 | Histone deacetylase inhibitors: Are they here to stay? |
| Q33705588 | Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions |
| Q36001847 | Histone deacetylase inhibitors: clinical implications for hematological malignancies |
| Q35592607 | Histone deacetylase inhibitors: emerging mechanisms of resistance. |
| Q37821337 | Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect |
| Q38960006 | Honokiol induces cell cycle arrest and apoptosis via inhibiting class I histone deacetylases in acute myeloid leukemia |
| Q39401953 | Hyper-activation of WNT/β-catenin signaling pathway mediates anti-tumor effects of histone deacetylase inhibitors in acute T lymphoblastic leukemia |
| Q46251027 | Induction of colon and cervical cancer cell death by cinnamic acid derivatives is mediated through the inhibition of Histone Deacetylases (HDAC). |
| Q33439519 | Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies |
| Q36548059 | Inhibition of class I histone deacetylases in non-small cell lung cancer by honokiol leads to suppression of cancer cell growth and induction of cell death in vitro and in vivo |
| Q28534761 | Inhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphoma |
| Q39705077 | Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage |
| Q34496371 | Inhibition of histone deacetylases 1 and 3 protects injured retinal ganglion cells |
| Q36799721 | Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat). |
| Q31101656 | Interferon regulatory factor-8 is important for histone deacetylase inhibitor-mediated antitumor activity |
| Q33392979 | Isoform-selective HDAC inhibitors: Closing in on translational medicine for the heart |
| Q36712802 | L-acetylcarnitine causes rapid antidepressant effects through the epigenetic induction of mGlu2 receptors. |
| Q34695894 | Ligand Based Pharmacophore Modeling and Virtual Screening Studies to Design Novel HDAC2 Inhibitors |
| Q39142767 | Loss of histone deacetylases 1 and 2 in hepatocytes impairs murine liver regeneration through Ki67 depletion |
| Q36850845 | MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor |
| Q57272449 | MLL-aberrant leukemia: complete cytogenetic remission following treatment with a histone deacetylase inhibitor (HDACi) |
| Q24629065 | Macrocyclic histone deacetylase inhibitors |
| Q37524412 | Manipulating the epigenome for the treatment of urological malignancies |
| Q36994177 | Marine-derived angiogenesis inhibitors for cancer therapy |
| Q37296330 | Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial |
| Q58614572 | Molecular prescreening to select patient population in early clinical trials |
| Q35001132 | Myelodysplastic syndrome and histone deacetylase inhibitors: "to be or not to be acetylated"? |
| Q48181021 | New 5-Aryl-Substituted 2-Aminobenzamide-Type HDAC Inhibitors with a Diketopiperazine Group and Their Ameliorating Effects on Ischemia-Induced Neuronal Cell Death |
| Q37854715 | New drug therapies in peripheral T-cell lymphoma |
| Q34380256 | New perspectives of valproic acid in clinical practice. |
| Q38315779 | New therapies in non-Hodgkin lymphoma |
| Q39280883 | Notch1 signaling is irresponsible to the anti-leukemic effect of HDACis in B-ALL Nalm-6 cells |
| Q39581390 | Novel cinnamyl hydroxyamides and 2-aminoanilides as histone deacetylase inhibitors: apoptotic induction and cytodifferentiation activity |
| Q47728772 | Novel insights into appropriate encapsulation methods for bioactive compounds into polymers: a study with peptides and HDAC inhibitors |
| Q50023818 | Novel therapeutics in glaucoma management |
| Q33390343 | Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis |
| Q64883255 | Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas. |
| Q28535006 | Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51 |
| Q38806260 | Panobinostat for the management of multiple myeloma |
| Q28533896 | Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cells |
| Q33415594 | Pharmacokinetic/Pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patients |
| Q37011621 | Pharmacokinetics-pharmacodynamics and antitumor activity of mercaptoacetamide-based histone deacetylase inhibitors |
| Q33394324 | Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma |
| Q33402040 | Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors |
| Q30416647 | Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small-cell lung cancer |
| Q39202249 | Physical interaction between MYCN oncogene and polycomb repressive complex 2 (PRC2) in neuroblastoma: functional and therapeutic implications. |
| Q33633898 | Polycomb target genes are silenced in multiple myeloma |
| Q41873212 | Post-training intrahippocampal inhibition of class I histone deacetylases enhances long-term object-location memory |
| Q26769594 | Potential use of histone deacetylase inhibitors in cancer therapy |
| Q35742395 | Preclinical antitumor activity of ST7612AA1: a new oral thiol-based histone deacetylase (HDAC) inhibitor. |
| Q37324186 | Profile of panobinostat and its potential for treatment in solid tumors: an update |
| Q28743986 | Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model |
| Q45948898 | Pure curcumin increases the expression of SOCS1 and SOCS3 in myeloproliferative neoplasms through suppressing class I histone deacetylases. |
| Q64910084 | Quantitative Proteomic Analysis Reveals the Sites Related to Acetylation and Mechanism of ACY-1215 in Acute Liver Failure Mice. |
| Q53416230 | Quantitative phosphoproteomic analysis reveals γ-bisabolene inducing p53-mediated apoptosis of human oral squamous cell carcinoma via HDAC2 inhibition and ERK1/2 activation. |
| Q36913828 | Real-time imaging of the dynamics of death receptors and therapeutics that overcome TRAIL resistance in tumors |
| Q37121662 | Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. |
| Q36027160 | RhoB upregulation leads to either apoptosis or cytostasis through differential target selection. |
| Q37226511 | Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies |
| Q33390876 | Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. |
| Q34729026 | Romidepsin: evidence for its potential use to manage previously treated cutaneous T cell lymphoma |
| Q38246144 | Selective class IIa HDAC inhibitors: myth or reality |
| Q39336516 | Selenium-containing histone deacetylase inhibitors for melanoma management |
| Q37961728 | Small-molecule chromatin-modifying agents: therapeutic applications |
| Q42744479 | Synergetic effects of DNA demethylation and histone deacetylase inhibition in primary rat hepatocytes |
| Q36843733 | Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo |
| Q37825891 | Targetable molecular pathways in classical Hodgkin's lymphoma. |
| Q34414452 | Targeting histone deacetyalses in the treatment of B- and T-cell malignancies |
| Q38066990 | Targeting histone deacetylase in thyroid cancer. |
| Q59132751 | The HDAC Inhibitor Quisinostat (JNJ-26481585) Supresses Hepatocellular Carcinoma alone and Synergistically in Combination with Sorafenib by G0/G1 phase arrest and Apoptosis induction |
| Q28477188 | The HDAC inhibitor FK228 enhances adenoviral transgene expression by a transduction-independent mechanism but does not increase adenovirus replication |
| Q64277594 | The Histone Deacetylase Inhibitor AN7, Attenuates Choroidal Neovascularization in a Mouse Model |
| Q35890561 | The Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for Treatment of Mycosis Fungoides/Sezary Syndrome Alone or with Doxorubicin |
| Q58792448 | The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease |
| Q33398014 | The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancer |
| Q40416435 | The epigenetic regulation of Dicer and microRNA biogenesis by Panobinostat |
| Q38480031 | The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models |
| Q39652513 | The histone deacetylase inhibitor butyroyloxymethyl diethylphosphate (AN-7) protects normal cells against toxicity of anticancer agents while augmenting their anticancer activity |
| Q39695495 | The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell lines |
| Q35953399 | The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines. |
| Q34602263 | The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma |
| Q37280189 | The role for epigenetic modifications in pain and analgesia response. |
| Q38071321 | Toxicological and metabolic considerations for histone deacetylase inhibitors |
| Q38342281 | Treatment-related symptom management in patients with multiple myeloma: a review |
| Q28082910 | Trial Watch: Proteasomal inhibitors for anticancer therapy |
| Q43105772 | Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study |
| Q89862635 | [Research Progress of Epigenetics in Pathogenesis and Treatment of Malignant Tumors] |
Search more.